



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

February 18, 2020

Via E-mail  
Manmeet S. Soni  
Chief Financial Officer  
Reata Pharmaceuticals, Inc.  
2801 Gateway Drive  
Suite 150  
Irving, TX 75063

**Re: Reata Pharmaceuticals, Inc.  
Form 8-K  
Exhibit No. 10.1 - Amended and Restated License Agreement, dated as of October 9,  
2019  
Filed October 10, 2019  
File No. 001-37785**

Dear Mr. Soni:

We have concluded our assessment of your redacted exhibit for compliance with applicable form requirements and will process your supplemental response and related materials in accordance with your request.

Sincerely,

Division of Corporation Finance